Clinical Trial: Real-world Outcome of Zongertinib in Japan (J-HERZ)

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07926308) titled 'Real-world Outcome of Zongertinib in Japan (J-HERZ)' on Nov. 03.

Brief Summary: This study aims to evaluate the real-world effectiveness and safety of zongertinib across treatment lines and human epidermal growth factor receptor 2 (HER2) mutation subtypes in Japanese patients with HER2-mutated non-small cell lung cancer (NSCLC).

Study Start Date: Nov. 17

Study Type: OBSERVATIONAL

Condition: Non-small Cell Lung Cancer

Intervention: DRUG: Zongertinib

Zongertinib

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Boehringer Ingelheim

Published by HT Digital Content Services with permission from Health Daily Digest....